“We are very happy and proud to be able to present an important commercial milestone for both companies. The interest in commercializing ASTar has been very strong from a number of global companies. We are thrilled to be working with Thermo Fisher and especially appreciate their global reach. We share a common market view and agree on how infection diagnosis can be improved.” said Jonas Jarvius, CEO of Q-linea.
Thermo Fisher Scientific™ will have the exclusive right to offer ASTar to the market in all geographies, with the exception that Q-linea can penetrate the Swedish market. The partnership is exclusive to both companies regarding fast AST testing. The two companies will work closely together to provide customers with a comprehensive AST portfolio.
Thermo Scientific Sensititre™ Complete Automated AST System is the industry standard for traditional MIC determination. Combining Thermo Fisher's long tradition, experience and strength in the field together with Q-linea's unique system for rapid and fully automatic AST analysis has the potential to greatly improve and speed up the diagnosis for patients with severe infectious diseases.
“Thermo Fisher is a true market leader but is also a first in line in bringing new antibiotic preparations to the market for testing which is, of course, interesting for the future." said Jonas Jarvius, CEO of Q-linea.
“We are very excited by this partnership with Q-linea” said Christophe Fraudeau, President Microbiology, Thermo Fisher Scientific. “Our distribution agreement for the Q-linea ASTar technology will enable our customers to streamline their workflow.”
Want more of the latest science news straight to your inbox? Become a SelectScience member for free today>>